Press Releases
Search
-
27 Jun 2023
Press Release
Jennifer Zinn appointed Executive Vice President of Clinical Operations
Marcy-l’Étoile, France – June 27th, 2023. bioMérieux, a world leader in the field of in vitro diagnostics, announces the appointment of Jennifer Zinn as Executive Vice President of Clinical Operations...
-
14 Jun 2023
Appointments
bioMérieux evolves its governance
As of July 1st, 2023, Alexandre Mérieux will become Executive Chairman and Pierre Boulud Chief Executive Officer.
-
09 May 2023
Press Release
bioMérieux receives US FDA CLIA-waiver for the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) Clinical Laboratory Improvement Amendments (CLIA) waiver for the fast and accurate multiplex PCR*-based BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini. This waiver comes in addition to the 510(k) clearance obtained last April.
-
27 Apr 2023
Press Release
bioMérieux – First-Quarter 2023 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2023. Consolidated sales totaled €906 million in the first quarter of 2023, up 8.2% from €837 million in the year‑earlier period.
-
14 Apr 2023
Press Release
Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement
Oxford Nanopore Technologies plc and bioMérieux SA, a world leader in the field of in vitro diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.
-
13 Apr 2023
Press Release
bioMérieux receives US FDA 510(k) clearance for the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
bioMérieux has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the fast and accurate multiplex PCR*-based BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini. bioMérieux will immediately apply for Clinical Laboratory Improvement Amendments (CLIA) waiver for the test.